Supernus Pharmaceuticals traded at $33.00 this Thursday September 29th, decreasing $0.41 or 1.23 percent since the previous trading session. Looking back, over the last four weeks, Supernus Pharmaceuticals lost 1.49 percent. Over the last 12 months, its price rose by 23.73 percent. Looking ahead, we forecast Supernus Pharmaceuticals to be priced at 32.09 by the end of this quarter and at 29.31 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
33.28
Daily Change
-0.39%
Yearly
24.78%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 7,704.00 920.00 13.56% -9.83%
Abbott 98.29 -0.43 -0.44% -16.80%
Aurora Cannabis Inc 1.70 -0.07 -3.95% -80.62%
Aerie Pharmaceuticals 15.12 0 0% 32.63%
ANI Pharmaceuticals 31.63 -0.56 -1.74% -3.63%
Bristol-Myers Squibb 71.76 -0.35 -0.49% 21.28%
Cara Therapeutics 9.11 0.10 1.11% -41.04%
Corcept Therapeutics 25.54 -0.50 -1.92% 29.78%
Endo International 0.10 -0.003 -2.76% -96.84%
Horizon Pharma 62.69 -1.15 -1.80% -42.77%
Jazz Pharmaceuticals 132.42 3.48 2.70% 1.70%
Lannett 0.46 -0.01 -1.17% -84.57%
Eli Lilly 330.01 -4.37 -1.31% 42.83%
Marinus Pharmaceuticals 7.02 0.04 0.50% -38.31%
Pacira 54.24 0.10 0.18% -3.14%
Pfizer 44.16 -0.27 -0.61% 2.67%
Perrigo 35.95 -0.66 -1.80% -24.04%
Revance Therapeutics 25.67 0.73 2.93% -7.86%
Supernus Pharmaceuticals 33.28 -0.13 -0.39% 24.78%
Teva Pharmaceutical Industries 7.82 -0.14 -1.76% -19.71%
United Therapeutics 207.94 -3.14 -1.49% 12.66%
Canopy Growth Corp 3.82 -0.32 -7.73% -78.23%
Xeris Pharmaceuticals Inc 1.59 0.01 0.63% -35.10%

Indexes Price Day Year
USND 10738 -314.13 -2.84% -25.68%
US2000 1675 -40.31 -2.35% -24.02%

Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.